Research Overview Table
Chemical and Molecular Characteristics
Ipamorelin is composed of Aib, histidine, D-2-naphthylalanine, D-phenylalanine, and lysinamide. The peptide therefore contains both a non-proteinogenic residue and D-configured amino acid residues. Its structure also includes an imidazole-containing histidine residue and aromatic groups contributed by the naphthylalanine and phenylalanine residues.
These structural features give Ipamorelin a defined stereochemical and chemical architecture. PubChem lists eight hydrogen-bond donors, eight hydrogen-bond acceptors, 19 rotatable bonds and a topological polar surface area of 240 Ų.
Certificates:
Mechanism of Action Under Investigation
Ipamorelin interacts with the growth hormone secretagogue receptor (GHSR), also described in the original Ipamorelin research as the GHRP-like receptor. Receptor-antagonist experiments showed that Ipamorelin-induced growth hormone release occurs through this receptor pathway rather than through the growth hormone-releasing hormone (GHRH) receptor.
Following receptor activation, Ipamorelin stimulates growth hormone release from pituitary cells. This was demonstrated in primary rat pituitary cell preparations and subsequently investigated in rat and swine models. The original study also compared Ipamorelin with GHRP-6 and GHRP-2 to characterize its receptor mediated activity and selectivity for growth hormone release.
The Ipamorelin-specific literature establishes the GHSR/GHRP-receptor pathway and subsequent growth hormone release as the central mechanism under investigation. The published Ipamorelin work does not fully define every intracellular signaling event occurring between receptor activation and hormone secretion, so broader GHSR signaling mechanisms should not be presented as specifically established for Ipamorelin.
Scientific Research Context
Ipamorelin appears in the scientific literature as a synthetic growth hormone secretagogue investigated in experimental and clinical research. The evidence base began with laboratory and animal research and later expanded to human pharmacokinetic and pharmacodynamic studies. Overall, the published literature remains relatively limited and comes primarily from in vitro and preclinical animal models. With a smaller body of human research.
Ipamorelin Biology and Biological Pathways
Primary Biological Function
The primary biological function investigated with Ipamorelin is regulation of growth hormone secretion. Growth hormone is produced by somatotroph cells in the anterior pituitary and released into circulation. Ipamorelin research examines this endocrine function because changes in GH secretion provide a direct way to study its effects on the growth hormone system.
Relevant Metabolic or Signaling Pathways
The GH–IGF-1 axis is the main endocrine pathway relevant to Ipamorelin research. Researchers investigate this pathway because GH and IGF-1 are connected signals involved in growth and metabolic regulation. Published Ipamorelin research has examined changes in GH and downstream IGF-1 activity, providing a basis for studying how GH-axis regulation relates to downstream endocrine signaling.
Tissue-Specific Biology
The anterior pituitary is the primary tissue relevant to Ipamorelin biology because its somatotroph cells produce growth hormone. Bone and skeletal muscle are also relevant to the published Ipamorelin literature because the GH axis is connected to musculoskeletal biology. Research in these tissues helps examine the biological relationship between GH regulation, bone formation, and skeletal muscle function.
Experimental Biomarkers
Growth hormone concentration is the principal biomarker used in Ipamorelin research. Other measurements reported in the literature include IGF-1, IGF-binding proteins, pituitary GH content, bone formation markers, and bone resorption markers. These measurements allow researchers to examine different biological components associated with the GH axis and related tissue biology.
Laboratory Investigation Methods
Researchers have investigated ipamorelin using pituitary cell assays, hormone measurements, pharmacokinetic analysis, and tissue based assessments. These methods allow researchers to examine Ipamorelin biology at the cellular, endocrine and tissue levels.
Experimental Models Used in Published Research
Researchers have studied ipamorelin in primary rat pituitary cells, rats, swine and humans. These models differ in biological complexity and translational relevance. The main limitations are the simplified nature of isolated cells, species differences in animal models, and the limited scope of the available human research.
Primary Rat Pituitary Cell Models
Primary rat pituitary cells provide an in vitro model for Ipamorelin research. Their main limitation is that isolated cells do not reproduce the interactions of the intact endocrine system. Findings from rat-derived cells also cannot be directly generalized to human pituitary biology.
Rat Models
Rat models are represented in the published Ipamorelin literature. Their main limitation is species-specific physiology. So findings from rats cannot be assumed to directly represent human biology.
Swine Models
Swine have also been used as a larger-animal model for Ipamorelin research. Their main limitation is that swine remain biologically distinct from humans, so findings cannot be assumed to directly reflect human physiology.
Human Studies
Healthy adult volunteers have been studied in controlled Ipamorelin research. The main limitation is that the available human evidence comes from a limited pharmacokinetic and pharmacodynamic study population, so it does not represent the broader human population.
Ipamorelin Published Research
Growth Hormone Secretion
Growth hormone secretion is the main research focus for Ipamorelin. Published studies examine the magnitude, duration, and selectivity of GH release and compare its activity with other growth hormone secretagogues. The literature also examines whether Ipamorelin changes the release of other pituitary hormones, including ACTH, cortisol, FSH, LH, PRL, and TSH.
Pharmacokinetics and Pharmacodynamics
Published research has examined Ipamorelin’s pharmacokinetic and pharmacodynamic profile, including systemic clearance, excretion, intranasal bioavailability, circulating peptide concentrations and the relationship between Ipamorelin exposure and GH release.
Bone and Skeletal Muscle Biology
Published research has examined longitudinal bone growth, bone mineral content, bone formation and skeletal muscle strength in relation to Ipamorelin. The studies specifically evaluated these skeletal and muscle outcomes as distinct areas of investigation.
Gastrointestinal Motility
Published research has examined gastrointestinal motility, including postoperative ileus, colonic transit, gastric emptying, and gastric smooth-muscle contractility. The literature therefore covers both intestinal transit and gastric motility as areas of Ipamorelin research.
Limitations of Current Research
Evidence Is Predominantly Preclinical
Much of the Ipamorelin literature comes from preclinical research. This limits how far the findings can be applied to human biology. Results from experimental systems can identify biological effects for further study, but they do not establish whether the same findings occur in humans.
Human Clinical Evidence
Human evidence on Ipamorelin is still limited in breadth. The published clinical literature includes a small number of focused studies, so there is not enough evidence to determine how consistently the findings apply across different populations or over longer periods.
Species Differences
Findings from animal studies may not directly apply to humans because physiology and biological responses can differ between species. This limits how directly findings from preclinical Ipamorelin research can be applied to human biology.
Study Design Limitations
Published studies use different designs, endpoints, exposure conditions, and research questions, which makes direct comparison difficult. The human postoperative ileus trial, for example, was explicitly described as a small proof-of-concept study with patients having a broad range of underlying conditions.
Independent Replication
The published Ipamorelin literature includes relatively few studies addressing the same research questions. This makes it difficult to judge whether individual findings would remain consistent when tested independently. The evidence therefore has limited support from repeated findings across separate research groups.
Long-Term Evidence
Long term evidence for Ipamorelin is limited. Published human studies have generally examined short treatment or observation periods, with one clinical trial administering Ipamorelin for up to seven days. The literature therefore provides little information about responses or effects over longer periods.
Analytical Documentation
HPLC provides chromatographic purity data and can detect related substances and impurities. LC-MS provides molecular-mass data for identity confirmation and can help characterize related peptide species. NMR provides structural information and can confirm structural features of the peptide. These methods assess different analytical attributes of the same material.
A Certificate of Analysis (COA) documents the analytical results for a specific batch. It may report identity, purity, content and other tested specifications. Researchers can use these records to check the material and its reported analytical results before laboratory use.
Analytical documentation verifies product identity and quality, not biological performance.
Storage and Laboratory Handling
Store the material at 2–8°C under the conditions specified for the product. Keep the material in its original container and keep the container tightly closed during storage. Maintain the recommended temperature throughout storage to help preserve the material’s stated quality.
Handle the material using clean laboratory practices and appropriate equipment. Qualified laboratory personnel should minimize unnecessary exposure during handling and keep the container closed when not in use. Clean handling helps prevent contamination and supports proper laboratory storage and handling.
Frequently asked questions
Why choose us?
Direct SARMs is an established supplier of research peptides. We are committed to product quality, reliable service, and helpful customer support.
Our European-made products undergo rigorous purity testing, with clear product information provided for each research material. We also aim to provide dependable shipping and a smooth ordering experience.
Our support team is available to assist with orders, shipping, payments, and general questions. At Direct SARMs, we aim to make the research supply process simple, clear, and reliable.